Brookline Capital Markets Reiterates Buy Rating, $143 PT on CRISPR Therapeutics (CRSP) on "Encouraging" New CTX130 Data
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $143.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
